Expert Speaker Faculty:
Anne-Ulrike Trendelenburg
Director, Head of MSD Cambridge, Novartis Institutes for Biomedical Research (NIBR), Musculoskeletal Disease Area (MSD)
Novartis
Barry Byrne
Associate Chair of Pediatrics & Director, Powell Gene Therapy Center
University of Florida
Jeffrey Chamberlain
Professor, Departments of Neurology, Medicine, and Biochemistry
University of Washington
Kevin Flanigan
Director, Center for Gene Therapy, Nationwide Children’s Hospital; Professor
The Ohio State University
Kevin Whittlesey
Vice President, Translational Medicine, Project Leader for Neuromuscular Disorders
4DMT
Luk Vandenberghe
Grousbeck Associate Professor in Gene Therapy, Harvard; Co-Founder & Chief Science Advisor
Affinia Therapeutics
Petra Kaufmann
Senior Vice President, Clinical Development/ Analytics & Translational Medicine
Novartis Gene Therapies
Michael Binks
Vice President & Head of Rare Disease Clinical Research, RDRU, Worldwide Research & Development
Pfizer
